[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Viking Therapeutics, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":111},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,63,90],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100659708","phase-3-oral-vk2735-for-weight-management-phase-3-sunrise-1-100659708",false,"NCT07868835","Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)","A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 68-Week Efficacy and Safety Study of VK2735 Administered Orally for Weight Management in Participants Without Type 2 Diabetes Mellitus Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition","Inclusion Criteria:\n\n1. Age ≥18 years of age at the time of signing the informed consent.\n2. Body mass index (BMI) ≥30 kg\u002Fm2 OR ≥27 kg\u002Fm2 with at least one weight-related co-morbid condition (treated or untreated).\n\n   * Weight-related co-morbid conditions include hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease.\n   * Cardiovascular disease includes, for example, ischemic cardiovascular disease, NYHA Functional Class I-III heart failure.\n   * BMI calculated at the screening visit will be used to determine eligibility.\n\nExclusion Criteria:\n\n1. History of or current clinically significant medical disorder that, in the opinion of the Investigator, does not support study participation\n2. Self-reported body weight change of 5% or more within 3 months of screening\n3. Have a prior or planned surgical treatment for obesity such as a gastric sleeve, lap band or any form of bariatric surgery (excluding liposuction or abdominoplasty if performed \\>1 year prior to screening)\n4. Have or plan to have endoscopic and\u002For device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as mucosal ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line)\n5. Current or past diagnosis of diabetes mellitus (including type 1, type 2, except gestational diabetes). If a participant has had gestational diabetes, they are allowed to be enrolled as long as the glycemic status has returned to normal levels after 12 months of completion of pregnancy\n6. Treatment with glucose-lowering agent(s) within 90 days before screening\n7. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)\n8. History of acute or chronic pancreatitis","ALL","18 Years",{"count":19,"type":20},560,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg\u002Fm2) or overweight (BMI ≥ 27kg\u002Fm2) adults with at least one weight-related comorbidity without type 2 diabetes mellitus.",[26],"Weight Loss",[28,29,26],"Body Weight Changes","Body Weight","NOT_YET_RECRUITING","2026-10-05",{"date":33,"type":34},"2026-10-09","ACTUAL",{"date":36,"type":20},"2026-10-15",{"date":38,"type":20},"2028-08",{"name":40,"class":41},"Viking Therapeutics, Inc.","INDUSTRY",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":51,"conditions":52,"keywords":53,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":57,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":4},"100659626","phase-3-oral-vk2735-for-weight-management-in-adults-with-type-2-diabetes-mellitus-phase-3-sunrise-2-100659626","NCT07868939","Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)","A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 68-Week Efficacy and Safety Study of VK2735 Administered Orally for Weight Management in Participants With Type 2 Diabetes Mellitus Who Are Obese, or Overweight","Inclusion Criteria:\n\n1. Age ≥18 years of age at the time of signing the informed consent.\n2. Body mass index (BMI) ≥ 27 kg\u002Fm2\n3. Have Type 2 Diabetes Mellitus according to the American Diabetes Association (See Section 12.5), with HbA1c ≥ 7% to ≤ 11% at screening, on stable therapy for the last 3 months prior to Screening. Participants with HbA1c between 6.5%-6.9% or 11.0%-11.5% are allowed to have a single HbA1c retesting to confirm eligibility. Type 2 Diabetes Mellitus may be treated with diet\u002Fexercise alone or any oral glycemic-lowering agent (as per local labeling), EXCEPT for amylin analogues or dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1R agonists or dual GLP-1\u002F glucose-dependent insulinotropic polypeptide (GIP) receptor agonists.\n\nExclusion Criteria:\n\n1. History of or current clinically significant medical disorder that, in the opinion of the Investigator, does not support study participation\n2. Self-reported body weight change of 5% or more within 3 months of screening\n3. Have a prior or planned surgical treatment for obesity such as a gastric sleeve, lap band or any form of bariatric surgery (except for liposuction or abdominoplasty if performed \\>1 year prior to screening)\n4. Have or plan to have endoscopic and\u002For device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as mucosal ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line)\n5. Have Type 1 Diabetes Mellitus, history of ketoacidosis or hyperosmolar state\u002Fcoma or any other types of diabetes except Type 2 Diabetes Mellitus (T2DM)\n6. Have had 1 or more episodes of severe hypoglycemia and\u002For 1 or more episode of hypoglycemia unawareness within 6 months of screening\n\n   • Note: Severe hypoglycemia episodes should be considered when severe cognitive impairment requiring the assistance of another person occurs and the administration of carbohydrate, glucagon, or other resuscitative actions are required. Blood glucose (BG) measurements may not be available during such an event, but neurological recovery attributable to the restoration of BG to normal is considered sufficient evidence that the event was induced by a low BG concentration. If BG measurements are available, the levels associated with severe hypoglycemia are BG \\\u003C 54 mg\u002FdL.\n7. Have at least 2 confirmed fasting self-monitoring blood glucose (SMBG) values \\> 270 mg\u002FdL (on 2 non-consecutive days) within 4 weeks prior to randomization\n8. Have non-proliferative diabetic retinopathy that requires acute treatment OR diabetic macular edema OR proliferative diabetic retinopathy identified during a dilated fundoscopy examination performed within 3 months of screening. Please see Section 7.6.\n9. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)\n10. History of acute or chronic pancreatitis\n11. Thyroid disease that is not controlled (Thyroid stimulating hormone (TSH) outside normal range by central lab at screening; one repetition during screening is allowed). Participants with previous history of partial\u002Ftotal thyroidectomy or hypothyroidism may be included, provided their hormone replacement dose has been stable for 3 months prior to screening.",{"count":19,"type":20},[23],"This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg\u002Fm2) or overweight (BMI ≥ 27 kg\u002Fm2) adults with Type 2 Diabetes Mellitus.",[26],[54,55,56],"body weight changes","body weight","weight loss",{"date":33,"type":34},{"date":59,"type":20},"2026-10-16",{"date":61,"type":20},"2028-12",{"name":40,"class":41},{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":21,"phases":73,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},"100658016","phase-1-a-phase-1-study-of-vk3019-in-overweight-and-obese-adults-without-comorbidities-100658016","NCT07846033","A Phase 1 Study of VK3019 in Overweight and Obese Adults Without Comorbidities","A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VK3019, an Amylin and Calcitonin Receptor Agonist, in Overweight and Obese Adults Without Comorbidities","Inclusion Criteria:\n\n* Must be capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF).\n* Participants must be medically healthy, with no significant medical history, have no clinically significant abnormalities on physical examination at Screening and\u002For before administration of the initial dose of IP in the opinion of the Investigator.\n* Body mass index ≥ 27 kg\u002Fm2 and \\\u003C 40 kg\u002Fm2.\n* Willing to comply with contraceptive requirements.\n\nExclusion Criteria:\n\n* Participants with any level of disease or organ system dysfunction as identified during physical examination, medical history or laboratory testing, as assessed by the Investigator.\n* Any surgical or medical condition (active or chronic) that may interfere with IP distribution, metabolism, excretion, or drug absorption.\n* History or presence of clinically significant acute or unstable cerebrovascular (stroke), hepatic, renal, gastrointestinal, pulmonary, immunological, endocrine, diabetes, hematological, oncological, or central nervous disorder that in the opinion of the Investigator would pose a significant risk for the participant.\n* Current or prior diagnosis of diabetes mellitus (including type 1, type 2, except gestational diabetes).\n* History of, or current, clinically significant liver disease, gallbladder disease (with the exception of Gilbert's Syndrome), as assessed by the Investigator.\n* History of drug or alcohol abuse (ie, \\>14 drinks\u002Fweek for women or 21 drinks\u002Fweek for men \\[1 drink = 150 mL of wine or 360 mL of beer or 45 mL of hard liquor\\]) within 12 months of Screening.","60 Years",{"count":72,"type":20},56,[74],"PHASE1","This is a Phase 1, randomized, double-blind, placebo-controlled single ascending dose (SAD) study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of VK3019 in overweight and obese adults without comorbidities.",[77],"Obese Adults",[79],"Weight loss","RECRUITING","2026-09-22",{"date":83,"type":34},"2026-09-29",{"date":85,"type":34},"2026-07-06",{"date":87,"type":20},"2026-11",{"name":40,"class":41},1,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":70,"enrollmentInfo":97,"targetDuration":4,"studyType":21,"phases":99,"briefSummary":100,"conditions":101,"keywords":102,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},"100657551","phase-1-a-phase-1-study-of-vk2735-in-obese-adults-without-comorbidities-100657551","NCT07838740","A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities","A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VK2735 Administration in Adults Who Are Obese (BMI ≥ 30 kg\u002Fm2) Without Comorbidities","Inclusion Criteria:\n\n* Must be capable of giving a signed informed consent form (ICF).\n* Must be medically healthy, with no significant medical history, have no clinically significant abnormalities on physical examination at Screening and\u002For before administration of the initial dose of IP in the opinion of the study Investigator.\n* BMI ≥ 30 kg\u002Fm2.\n* Willing to comply with contraceptive requirements.\n\nExclusion Criteria:\n\n* Participants with any level of disease or organ system dysfunction as identified during physical examination, medical history, or laboratory testing, as assessed by the Investigator.\n* Any surgical or medical condition (active or chronic) that may interfere with IP distribution, metabolism, excretion or drug absorption.\n* Any condition that might compromise safety or other endpoints in the study as judged by the Sponsor (or designee) or Investigator.\n* History or presence of clinically significant acute or unstable cerebrovascular (stroke), hepatic, renal, gastrointestinal, pulmonary, immunological, endocrine, hematological, oncological, or central nervous disorder that in the opinion of the Investigator would pose a significant risk for the participant.\n* Current or past diagnosis of diabetes mellitus (including type 1 and type 2, except gestational diabetes).\n* Have a personal or family history of medullary thyroid carcinoma (MTC) or have multiple endocrine neoplasia syndrome type 2 (MEN-2).\n* Alanine aminotransferase (ALT) level or aspartate transaminase (AST) level \\> 3.0 times the ULN for the reference range.\n* Impaired renal function with estimated glomerular filtration rate (eGFR) \\\u003C 60 mL\u002Fmin\u002F1.73 m2 as measured at Screening.",{"count":98,"type":20},270,[74],"The goal of this Phase 1, randomized, double-blind, placebo-controlled study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VK2735 in adults who are obese (BMI ≥ 30 kg\u002Fm2) without comorbidities.",[77],[79],{"date":104,"type":34},"2026-09-24",{"date":106,"type":34},"2025-11-18",{"date":108,"type":20},"2027-07",{"name":40,"class":41},2,""]